Zogenix (ZGNX) Gets a Buy Rating from William Blair

By Austin Angelo

In a report released today, Tim Lugo from William Blair maintained a Buy rating on Zogenix (ZGNXResearch Report). The company’s shares closed yesterday at $51.85.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 12.9% and a 43.9% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Aclaris Therapeutics Inc, and Acer Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $71.75 average price target, representing a 38.4% upside. In a report issued on April 5, Northland Securities also maintained a Buy rating on the stock with a $70 price target.

See today’s analyst top recommended stocks >>

Based on Zogenix’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.43 million. In comparison, last year the company had a GAAP net loss of $30.18 million.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.